secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001437749-22-028128
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

KemPharm appoints Christopher A. Posner to board of directors
-------------------------------------------------------------

- Christopher A. Posner appointed effective November 28, 2022 as Class II director with term expiring at 2023 annual meeting.
- Posner is President and CEO of Cara Therapeutics; brings experience in pharmaceutical commercial operations and product management.
- Received initial option grant for 22,500 shares vesting over three years; annual cash retainer of $40,000 under non-employee director policy.
- Eligible for additional annual option grant of 15,000 shares at each subsequent annual meeting where term continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774922028128/0001437749-22-028128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774922028128/kmph20221128_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-028128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer